| Print
INVENTIVA (IVA)
INVENTIVANot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Address
50, rue de Dijon
Daix
FRA
21121
Telephone
+33 380447500
Forecast key dates
| Name | Key Date |
|---|---|
| Inventiva SA Second Quarter Earnings Results for 2026 | 2026-09-25T00:00:00 |
| Inventiva SA Annual General Meeting for 2025 | 2026-05-22T09:00:00 |
| Inventiva SA Annual Report for 2025 | 2026-04-15T00:00:00 |
| Inventiva SA Fourth Quarter Earnings Conference Call for 2025 | 2026-03-27T08:00:00 |
| Inventiva SA Fourth Quarter Earnings Results for 2025 | 2026-03-26T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Inventiva SA Second Quarter Earnings Results for 2025 | 2025-09-25T00:00:00 |
| Canaccord Genuity 45th Annual Growth Conference | 2025-08-13T10:30:00 |
| Jefferies Global Healthcare Conference | 2025-06-04T01:30:00 |
| Inventiva SA Annual General Meeting for 2024 | 2025-05-22T09:00:00 |
| Inventiva SA Annual Report for 2024 | 2025-04-15T00:00:00 |
| Inventiva SA Fourth Quarter Earnings Conference Call for 2024 | 2025-03-27T08:00:00 |
| Inventiva SA Fourth Quarter Earnings Results for 2024 | 2025-03-26T00:00:00 |
| 43 rd Annual J.P. Morgan Healthcare Conference | 2025-01-15T18:45:00 |
| Stifel Healthcare Conference | 2024-11-18T00:00:00 |
| AASLD The Liver Meeting | 2024-11-15T00:00:00 |
| Guggenheim Global Healthcare Conference | 2024-11-11T00:00:00 |
| Portzamparc BNP Paribas Séminaire Biotech & Santé | 2024-10-08T00:00:00 |
| H.C. Wainwright 9th Annual MASH Investor Conference | 2024-10-07T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.